Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8922495 | Clinical and Translational Radiation Oncology | 2017 | 7 Pages |
Abstract
Our data suggest that RT should be considered for well-selected patients with HCC and PVTT for the purpose of improving local control and potentially prolonging the time to worsening venous obstruction and liver failure. When feasible, dose-escalation should be considered with a target BED of >75Â Gy if normal organ dose constraints can be safely met.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Emma B. Holliday, Randa Tao, Zachary Brownlee, Prajnan Das, Sunil Krishnan, Cullen Taniguchi, Bruce D. Minsky, Joseph M. Herman, Ahmed Kaseb, Kanwal Raghav, Claudius Conrad, Jean-Nicholas Vauthey, Thomas A. Aloia, Yun Shin Chun, Christopher H. Crane,